These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36876219)

  • 1. Impact of Season and Other Factors on Initiation, Discontinuation, and Switching of Systemic Drug Therapy in Patients with Psoriasis: A Retrospective Study.
    Liang H; Kirk B; Polinski JM; Yue X; Kilpatrick RD; Gelfand JM
    JID Innov; 2023 Mar; 3(2):100171. PubMed ID: 36876219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.
    Zhang HF; Gauthier G; Hiscock R; Curtis JR
    Arthritis Res Ther; 2014 Aug; 16(4):420. PubMed ID: 25146329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
    Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
    Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis.
    Akdogan N; Dogan S; Bostan E; Gulseren D; Yalici-Armagan B; Elcin G; Evans SE; Karaduman A; Atakan N
    Expert Rev Clin Pharmacol; 2021 Dec; 14(12):1535-1541. PubMed ID: 34519227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of serious infection in patients who are prescribed systemic biologic or nonbiologic agents for psoriasis: A large, single center, retrospective, observational cohort study.
    Carneiro C; Bloom R; Ibler E; Majewski S; Sable KA; Guido NJ; Day J; Nocadello S; Florek AG; West DP; Nardone B
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28796405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons.
    Wolf D; Skup M; Yang H; Fang AP; Kageleiry A; Chao J; Mittal M; Lebwohl M
    Clin Ther; 2017 Apr; 39(4):849-862.e6. PubMed ID: 28363696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
    Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
    Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.
    Song Y; Betts KA; Lu Y; Singh R; Clewell J; Griffith J
    Rheumatol Ther; 2019 Jun; 6(2):285-297. PubMed ID: 31055779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching Biologics in the Treatment of Psoriasis: A Multicenter Experience.
    Özkur E; Kıvanç Altunay İ; Oğuz Topal İ; Aytekin S; Topaloğlu Demir F; Özkök Akbulut T; Kara Polat A; Karadağ AS
    Dermatology; 2021; 237(1):22-30. PubMed ID: 31865339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users.
    Ighani A; Yu AM; Sandhu VK; Barankin B; Manolson MF
    J Cutan Med Surg; 2019; 23(2):148-156. PubMed ID: 30801221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies.
    Thai S; Zhuo J; Zhong Y; Xia Q; Chen X; Bao Y; Dhanda D; Priya L; Wu JJ
    J Dermatolog Treat; 2023 Dec; 34(1):2176708. PubMed ID: 36794863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that systemic therapies for psoriasis may reduce psoriatic arthritis occurrence.
    Solmaz D; Ehlebracht A; Karsh J; Bakirci S; McGonagle D; Aydin SZ
    Clin Exp Rheumatol; 2020; 38(2):257-261. PubMed ID: 31287403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database.
    Vasilakis-Scaramozza C; Persson R; Hagberg KW; Jick S
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1755-1763. PubMed ID: 31981426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis.
    Li P; Blum MA; Von Feldt J; Hennessy S; Doshi JA
    Value Health; 2010; 13(6):805-12. PubMed ID: 21054657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database.
    Husni ME; Chang E; Broder MS; Paydar C; Bognar K; Desai P; Klyachkin Y; Khilfeh I
    Open Access Rheumatol; 2022; 14():123-132. PubMed ID: 35734243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.